AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26831652 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol MDPI with integrated dose counter (2 inhalations/dose; 90 μg/inhalation) twice daily for up to 50 days
Number of subjects: 317
Study 26831652 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol MDPI with integrated dose counter
Number of subjects: 317
Study 26831652 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol MDPI
Number of subjects: 317
Study 26831844 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (160/4.5 μg, one inhalation twice daily and as needed)
Number of subjects: 478
Study 26832194 — intervention group
Group type: EXPERIMENTAL
Intervention: Tositumomab/Iodine-131 Tositumomab (TST/I-131 TST)
Number of subjects: 15
Study 26832367 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 14-3-3η protein levels ≥0.50 ng/ml
Number of subjects: 331
Study 26832367 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated levels of 14-3-3η during follow-up
Number of subjects: 331
Study 26832367 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreases of 14-3-3η levels by at least 0.76 ng/ml
Number of subjects: 331
Study 26832367 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 14-3-3η ≥0.19 ng/ml
Number of subjects: 331
Study 26832367 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal baseline 14-3-3η levels defined by ROC curves at 0.50 ng/ml
Number of subjects: 331
Study 26832367 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-3-3η, CRP, age and Abs
Number of subjects: 331
Study 26832753 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin at 150 mg once daily with non-boosted or ritonavir-boosted PIs
Number of subjects: 0
Study 26832753 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin at 300 mg every 3 days with boosted PI
Number of subjects: 0
Study 26832753 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 0
Study 26832753 — intervention group
Group type: EXPERIMENTAL
Intervention: Des-rifabutin
Number of subjects: 0
Study 26833097 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic evaluation including bone imaging and blood laboratory testing
Number of subjects: 54
Study 26833097 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood laboratory testing
Number of subjects: 54
Study 26834058 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg orally once per day
Number of subjects: 40
Study 26835133 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 1299
Study 26835134 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care as defined by their physician
Number of subjects: 300
Study 26835134 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome questionnaires
Number of subjects: 300
Study 26835134 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples for cellular, genetic and transcriptomic analyses
Number of subjects: 300
Study 26835148 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupus anticoagulant (LAC) presence
Number of subjects: 44
Study 26835148 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite antiphospholipid syndrome
Number of subjects: 44
Study 26835148 — intervention group
Group type: COMPARATOR
Intervention: Systemic lupus erythematosus (SLE)
Number of subjects: 44
Study 26835225 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 50 mg/day plus letrozole 2.5 mg/day
Number of subjects: 28
Study 26835225 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day plus letrozole 2.5 mg/day
Number of subjects: 28
Study 26835225 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 30 mg/day plus letrozole 2.5 mg/day
Number of subjects: 28
Study 26835225 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib combined with letrozole
Number of subjects: 28
Study 26835225 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 28
Study 26835906 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologicals treatment
Number of subjects: 84
Study 26836193 — intervention group
Group type: EXPERIMENTAL
Intervention: T3D-959 (0.3 to 3.0 mg/kg/day) for 28 days
Number of subjects: 2
Study 26836193 — intervention group
Group type: EXPERIMENTAL
Intervention: T3D-959 (0.5-1.0 μM) on frontal lobe slice cultures
Number of subjects: 2
Study 26836193 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest tested dose of T3D-959
Number of subjects: 2
Study 26836193 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 2
Study 26836793 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (150 mg twice daily)
Number of subjects: 234
Study 26836793 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg daily)
Number of subjects: 234
Study 26836793 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg twice daily)
Number of subjects: 234
Study 26836895 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged adults (age 50-64)
Number of subjects: 4097
Study 26836895 — intervention group
Group type: COMPARATOR
Intervention: Older adults (age 65-80)
Number of subjects: 4097
Study 26836895 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged adults (age 50-64) with dyspnea severity (modified Medical Research Council ≥ 2)
Number of subjects: 4097
Study 26836895 — intervention group
Group type: COMPARATOR
Intervention: Older adults (age 65-80) with dyspnea severity (modified Medical Research Council ≥ 2)
Number of subjects: 4097
Study 26836895 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in SPIROMICS study
Number of subjects: 4097
Study 26836896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) findings of infection, subpleural consolidation, and dynamic arborescent/linear air bronchogram
Number of subjects: 99
Study 26836896 — intervention group
Group type: EXPERIMENTAL
Intervention: Two dynamic linear/arborescent air bronchograms
Number of subjects: 99
Study 26836896 — intervention group
Group type: EXPERIMENTAL
Intervention: VPLUS-EAgram
Number of subjects: 99
Study 26836896 — intervention group
Group type: EXPERIMENTAL
Intervention: VPLUS
Number of subjects: 99
Study 26836938 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent depression group (n = 377)
Number of subjects: 1589
Study 26836938 — intervention group
Group type: EXPERIMENTAL
Intervention: New onset depression group (n = 226)
Number of subjects: 1589
Study 26836938 — intervention group
Group type: COMPARATOR
Intervention: Never depressed group (n = 869)
Number of subjects: 1589
Study 26836938 — intervention group
Group type: EXPERIMENTAL
Intervention: Remittent depression group (n = 117)
Number of subjects: 1589
Study 26837432 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Directed Activity Program (up to three additional 30-minute bouts of activities daily)
Number of subjects: 0
Study 26837432 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Directed Activity Program
Number of subjects: 0
Study 26837432 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 26837440 — intervention group
Group type: EXPERIMENTAL
Intervention: NBS20/eltrapuldencel-T (dendritic cell-based vaccine)
Number of subjects: 0
Study 26837440 — intervention group
Group type: COMPARATOR
Intervention: Targeted therapy and immunotherapy
Number of subjects: 0
Study 26838019 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg IV on days 3 and 5, 5HT3 receptor antagonist days 1-5, dexamethasone 20 mg days 1 and 2, 4 mg po bid days 6, 7, and 8
Number of subjects: 65
Study 26838022 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the PRO-CTCAE
Number of subjects: 109
Study 26838587 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CTA-SI-ASPECTS
Number of subjects: 110
Study 26838587 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCT-ASPECTS
Number of subjects: 110
Study 26838587 — intervention group
Group type: EXPERIMENTAL
Intervention: Recanalization
Number of subjects: 110
Study 26838587 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS at 24 hours
Number of subjects: 110
Study 26838587 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic intracranial hemorrhage
Number of subjects: 110
Study 26838587 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rankin scale score
Number of subjects: 110
Study 26838587 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality at 90 days
Number of subjects: 110
Study 26839391 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent procedures with ST
Number of subjects: 604
Study 26839391 — intervention group
Group type: COMPARATOR
Intervention: Stent procedures without ST
Number of subjects: 604
Study 26839391 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding covered stent grafts
Number of subjects: 604
Study 26839391 — intervention group
Group type: COMPARATOR
Intervention: No ST
Number of subjects: 604
Study 26839391 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of chronic total occlusion lesions
Number of subjects: 604
Study 26839391 — intervention group
Group type: EXPERIMENTAL
Intervention: In-stent restenosis lesions
Number of subjects: 604
Study 26839475 — intervention group
Group type: EXPERIMENTAL
Intervention: PNH patients with hemolysis (LDH ≥ 1.5 × ULN)
Number of subjects: 301
Study 26839475 — intervention group
Group type: COMPARATOR
Intervention: PNH patients with LDH < 1.5 × ULN
Number of subjects: 301
Study 26839475 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboembolism (TE)
Number of subjects: 301
Study 26839475 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal impairment
Number of subjects: 301
Study 26839475 — intervention group
Group type: EXPERIMENTAL
Intervention: PNH-cytopenia
Number of subjects: 301
Study 26839475 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hemolysis and 1 or more clinical symptoms (abdominal pain, chest pain, dyspnea)
Number of subjects: 301
Study 26839476 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber-enriched cereal flakes (DC)
Number of subjects: 13
Study 26839476 — intervention group
Group type: COMPARATOR
Intervention: Conventional cereal flakes (CC)
Number of subjects: 13
Study 26840420 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 282
Study 26840420 — intervention group
Group type: COMPARATOR
Intervention: Parental anxiety reduction
Number of subjects: 282
Study 26840494 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol-Enhanced Breast MRI (CE-BMRI)
Number of subjects: 906
Study 26840494 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced Breast MRI
Number of subjects: 906
Study 26840494 — intervention group
Group type: COMPARATOR
Intervention: Mammography alone
Number of subjects: 906
Study 26841930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/sofosbuvir fixed-dose combination tablet for 12 weeks
Number of subjects: 85
Study 26842272 — intervention group
Group type: EXPERIMENTAL
Intervention: Low adiponectin maternal levels in first trimester
Number of subjects: 1034
Study 26842272 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin D maternal levels in first trimester
Number of subjects: 1034
Study 26842272 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dysglycaemia during pregnancy
Number of subjects: 1034
Study 26843003 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain MRI scans
Number of subjects: 503
Study 26843355 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 102
Study 26843355 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 102
Study 26843355 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch plasty
Number of subjects: 102
Study 26843355 — intervention group
Group type: EXPERIMENTAL
Intervention: No vascular intervention
Number of subjects: 102
Study 26843482 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulants (NOACs) including dabigatran etexilate, rivaroxaban, apixaban, and edoxaban
Number of subjects: 0
Study 26843482 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs) including warfarin
Number of subjects: 0
Study 26843484 — intervention group
Group type: EXPERIMENTAL
Intervention: GMCI + SOC
Number of subjects: 182
Study 26843484 — intervention group
Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 182
Study 26843484 — intervention group
Group type: EXPERIMENTAL
Intervention: GMCI + SOC (in gross total resection patients)
Number of subjects: 182
Study 26843484 — intervention group
Group type: COMPARATOR
Intervention: SOC alone (in gross total resection patients)
Number of subjects: 182
Study 26843560 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab high-yield process (DAC-HYP)
Number of subjects: 31
Study 26844128 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn monitor (Polar Active) with feedback
Number of subjects: 276
Study 26844132 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotional media condition
Number of subjects: 217
Study 26844132 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network condition
Number of subjects: 217
Study 26844132 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 217
Study 26844166 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness Action Plan
Number of subjects: 181
Study 26844166 — intervention group
Group type: COMPARATOR
Intervention: Standard diet and activity counseling
Number of subjects: 181
Study 26844197 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert system-based, print-delivered physical activity intervention
Number of subjects: 232
Study 26844197 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 232
Study 26844269 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG spectral power, coherence, phase lag, Pearson and partial correlations, and epileptiform activity during awake, slow wave sleep, and REM sleep states
Number of subjects: 137
Study 26844275 — intervention group
Group type: EXPERIMENTAL
Intervention: RILA ≥ 12%
Number of subjects: 502
Study 26844275 — intervention group
Group type: EXPERIMENTAL
Intervention: No adjuvant hormonotherapy
Number of subjects: 502
Study 26844275 — intervention group
Group type: EXPERIMENTAL
Intervention: RILA < 12%
Number of subjects: 502
Study 26844275 — intervention group
Group type: EXPERIMENTAL
Intervention: RILA ≥ 20%
Number of subjects: 502
Study 26844275 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing values of RILA
Number of subjects: 502
Study 26844275 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis
Number of subjects: 502
Study 26844278 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E δ-tocotrienol (VEDT) 200 to 3200 mg daily for 13 days before surgery and one dose on the day of surgery
Number of subjects: 25
Study 26844278 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E δ-tocotrienol (VEDT) 200 to 1600 mg daily for 2 weeks before pancreatic surgery
Number of subjects: 25
Study 26844283 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator (SCE) therapy
Number of subjects: 15
Study 26844479 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitization regimen consisting of 2 doses of IVIG (2 g/kg), a single dose of rituximab (375 mg/m), and 4 doses of bortezomib (1.3 mg/m)
Number of subjects: 36
Study 26844479 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 36
Study 26844479 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitization regimen
Number of subjects: 36
Study 26844479 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 26844757 — intervention group
Group type: EXPERIMENTAL
Intervention: doxylamine-pyridoxine
Number of subjects: 0
Study 26845266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 1466
Study 26845266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1466
Study 26845282 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (administered for 6 weeks)
Number of subjects: 25
Study 26846118 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 1200
Study 26846118 — intervention group
Group type: COMPARATOR
Intervention: Water Immersion (WI)
Number of subjects: 1200
Study 26846118 — intervention group
Group type: COMPARATOR
Intervention: Air/Carbon Dioxide Insufflation (AICD)
Number of subjects: 1200
Study 26846166 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medicine (IM) approach, non-standardized and personalized, multimodal
Number of subjects: 10000
Study 26846377 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 0
Study 26846377 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-4
Number of subjects: 0
Study 26846377 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 26846377 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) in HDM murine model
Number of subjects: 0
Study 26846895 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV test proposed to each study participant
Number of subjects: 0
Study 26846895 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire including life-event interview
Number of subjects: 0
Study 26846895 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative exploratory study
Number of subjects: 0
Study 26846895 — intervention group
Group type: COMPARATOR
Intervention: Matched control group of people without disabilities
Number of subjects: 0
Study 26847010 — intervention group
Group type: EXPERIMENTAL
Intervention: DT gait measures combined with the digit span task
Number of subjects: 62
Study 26847010 — intervention group
Group type: EXPERIMENTAL
Intervention: DT gait measures combined with the auditory Stroop task
Number of subjects: 62
Study 26847010 — intervention group
Group type: EXPERIMENTAL
Intervention: DT gait measures combined with the mobile phone task
Number of subjects: 62
Study 26847010 — intervention group
Group type: EXPERIMENTAL
Intervention: DT cognitive measures (digit span task)
Number of subjects: 62
Study 26847010 — intervention group
Group type: EXPERIMENTAL
Intervention: DT cognitive measures (auditory Stroop task)
Number of subjects: 62
Study 26847118 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated Zilver PTX stent
Number of subjects: 907
Study 26847408 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to higher air pressure and higher humidity
Number of subjects: 1370
Study 26847408 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to cat's allergens
Number of subjects: 1370
Study 26847408 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of asthma and current ICS therapy
Number of subjects: 1370
Study 26847408 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC (exercise treadmill challenge) results
Number of subjects: 1370
Study 26847408 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported dyspnea/cough
Number of subjects: 1370
Study 26847408 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoconstriction induced during PE lesson
Number of subjects: 1370
Study 26847436 — intervention group
Group type: COMPARATOR
Intervention: PEEP trial at 4 cmH2O
Number of subjects: 20
Study 26847436 — intervention group
Group type: COMPARATOR
Intervention: PEEP trial at 12 cmH2O
Number of subjects: 20
Study 26847436 — intervention group
Group type: COMPARATOR
Intervention: PEEP trial (4 and 12 cmH2O)
Number of subjects: 20
Study 26847436 — intervention group
Group type: COMPARATOR
Intervention: Airway pressures and tidal volume normalized to body weight
Number of subjects: 20
Study 26848057 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (50 mg dose)
Number of subjects: 150
Study 26849144 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (N = 59)
Number of subjects: 205
Study 26849144 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (N = 71)
Number of subjects: 205
Study 26849144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (N = 75)
Number of subjects: 205
Study 26849144 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking resumption after cessation (T2)
Number of subjects: 205
Study 26849202 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (10 Hz, 120% motor threshold, 3000 pulses applied to the dorsolateral prefrontal cortex, MRI guided)
Number of subjects: 10
Study 26849202 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided localization
Number of subjects: 10
Study 26849202 — intervention group
Group type: COMPARATOR
Intervention: 5 cm rule and Beam F3 methods
Number of subjects: 10
Study 26849853 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP or R-CVP followed by (90) Y-IT (15 MBq/kg, maximum 1200 MBq) preceded by two infusions of 250 mg/m(2) rituximab
Number of subjects: 52
Study 26849853 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP or R-CVP followed by (90) Y-IT
Number of subjects: 52
Study 26850111 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) treatment administered by Korean medicine doctors (KMDs)
Number of subjects: 165
Study 26850111 — intervention group
Group type: COMPARATOR
Intervention: Non-long term follow-up group (n=48)
Number of subjects: 165
Study 26850111 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term follow-up group (n=117)
Number of subjects: 165
Study 26850512 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic plot method for estimating nondisplaceable fraction using baseline scans only.
Number of subjects: 7
Study 26850626 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial triglyceride content measured on magnetic resonance spectroscopy (1H-MRS) in patients with low LVEF (<50%)
Number of subjects: 50
Study 26850626 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial triglyceride content measured on magnetic resonance spectroscopy (1H-MRS) in patients with normal LVEF (≥50%)
Number of subjects: 50
Study 26850626 — intervention group
Group type: COMPARATOR
Intervention: Myocardial triglyceride content measured on magnetic resonance spectroscopy (1H-MRS) in controls
Number of subjects: 50
Study 26850626 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of myocardial UFA/TG ratio with LV mass
Number of subjects: 50
Study 26850626 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of myocardial UFA/TG ratio with LV end-diastolic volume (LVEDV)
Number of subjects: 50
Study 26850626 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of myocardial FA/TG ratio with LV mass
Number of subjects: 50